A speech disfluency, also spelled speech dysfluency, is any of various breaks, irregularities, or non-lexical vocables which occur within the flow of otherwise fluent speech. These include "false starts", i.e. words and sentences that are cut off mid-utterance; phrases that are restarted or repeated and repeated syllables; "fillers", i.e. grunts or non-lexical utterances such as "huh", "uh", "erm", "um", "well", "so", "like", and "hmm"; and "repaired" utterances, i.e. instances of speakers correcting their own slips of the tongue or mispronunciations (before anyone else gets a chance to). "Huh" is claimed to be a universal syllable. Fillers
Fillers are parts of speech which are not generally recognized as purposeful or containing formal meaning, usually expressed as pauses such as "uh", "like" and "er", but also extending to repairs ("He was wearing a black—uh, I mean a blue, a blue shirt"), and articulation problems such as stuttering. Use is normally frowned upon in mass media such as news reports or films, but they occur regularly in everyday conversation, sometimes representing upwards of 20% of "words" in conversation. Fillers can also be used as a pause for thought ("I arrived at, um—3 oclock"), and when used in this function are called hesitation markers or planners. Language-dependence
Research in computational linguistics has revealed a correlation between native language and patterns of disfluencies in spontaneously uttered speech. Besides that research, there are other subjective accounts reported by individuals.
In 1947, DES finally gained FDA approval for prescription to pregnant women who had diabetes as a method of preventing miscarriages. This led to the widespread prescription of DES to all pregnant women.In 1971, the FDA recommended against the prescription of DES to pregnant women. As a result, DES then began to see a withdraw from the US market starting in 1972 and in the European market starting in 1978, but the FDA still did not withdraw its approval for the use of DES in humans.DES was classified as a Group 1 carcinogen by the International Agency for Research on Cancer. After classification as a carcinogen, DES had its FDA approval withdrawn in 2000. DES is currently only in use for veterinary practices and in research trials as allowed by the FDA.Medical Ethics
Medical Ethics in regard to the approval and use of Diethylstilbestrol have been dismissed because of the actions of the FDA and pharmaceutical companies that were making DES at the time of its use. The Vice President of the American Drug Manufacturers Association, Carson Frailey, was employed by drug companies creating DES in order to help get it approved by the Food and Drug Administration (FDA). Nancy Langston, the author of The Retreat from Precaution: Regulating Diethylstilbestrol (DES), Endocrine Disruptors, and Environmental Health, states that "Frailey persuaded fifty-four doctors from around the country to write to the FDA, describing their clinical experiences with a total of more than five thousand patients.